Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: Hepatology. 2011 Feb 11;53(3):974–982. doi: 10.1002/hep.24132

Figure 5. Effect of a pan-caspase inhibitor on APAP toxicity in HepaRG cells.

Figure 5

(A) Caspase-3 activity was measured in cell lysates of untreated cells or 24h after APAP treatment (20 mM). As positive control, cells were treated with galactosamine and recombinant human TNF for 16.5h in the presence or absence of vehicle (Tris-buffer) or the pan-caspase inhibitor (CI) Z-VD-fmk (20 µM). (B) LDH release in untreated cells or 24h after APAP treatment. Some cells were pretreated for 1h with vehicle or CI before addition of 20 mM APAP. Data are expressed as mean ± SE for 4 independent cell preparations. *P<0.05 (compared to Ctrl) #P<0.05 (compared to APAP or G/TNF)